Capitalized at $1.9 million, Hitachi holds a 66% stake in the new company while Takeda Pharmaceutical holds the remaining 34%. The companies have said that Hitachi Inspharma will initially provide outsourcing services to Takeda Pharmaceutical. Details of how it will develop following this were not revealed.
The companies also revealed that upon expiration of the two-year joint venture period, Hitachi Inspharma will become a wholly owned subsidiary of Hitachi.
Hitachi Inspharma is expected to generate approximately $33.8 million in sales in fiscal 2006.
This article is from the CBROnline archive: some formatting and images may not be present.
CBR Online legacy content.